Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
The RP4 plasmid is a 60 kb self-transmissible IncPα plasmid with an extremely broad host range, stably maintained in Gram-negative bacteria and capable of conjugative DNA transfer to Gram-positive bacteria and yeasts. It encodes two main transfer regions, Tra1 and Tra2: Tra1 handles DNA processing via a relaxosome at the origin of transfer (oriT), involving proteins like TraI (relaxase), TraH, TraJ, and TraK, while Tra2 (core region with trbB-L genes) and traF form the mating pair formation (Mpf) system, creating a membrane-spanning apparatus for cell-to-cell contact, pilus production, and DNA transport through inner and outer membranes. Most Mpf proteins localize to the outer membrane, with TrbB in soluble/cytoplasmic membrane fractions, forming a multicomponent complex akin to a type IV secretion system (T4SS). RP4 serves as a model for plasmid biology and shares similarities with Agrobacterium Ti plasmid Vir regions for T-DNA transfer. It is not a human therapeutic target but a tool in synthetic biology for engineering conjugation in bacteria like E. coli and Pseudomonas. No drugs target RP4 directly, as it functions in bacterial genetics rather than human disease pathways.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on RP4 plasmid (RP4).